{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:47:30Z","timestamp":1770745650643,"version":"3.49.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1093\/carcin\/bgv002","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T02:41:45Z","timestamp":1421203305000},"page":"469-477","source":"Crossref","is-referenced-by-count":33,"title":["TRIB2 as a biomarker for diagnosis and progression of melanoma"],"prefix":"10.1093","volume":"36","author":[{"given":"Richard","family":"Hill","sequence":"first","affiliation":[]},{"given":"Ravi Kiran Reddy","family":"Kalathur","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Cola\u00e7o","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Futschik","sequence":"additional","affiliation":[]},{"given":"Wolfgang","family":"Link","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2015,1,13]]},"reference":[{"key":"key\n\t\t\t\t20170503060032_CIT0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"(2007)","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170503060032_CIT0002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2004.05708.x","article-title":"Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma","volume":"150","author":"Lens","year":"(2004)","journal-title":"Br. J. Dermatol"},{"key":"key\n\t\t\t\t20170503060032_CIT0003","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"(2004)","journal-title":"N. Engl. J. Med"},{"key":"key\n\t\t\t\t20170503060032_CIT0004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/era.09.25","article-title":"Current systemic therapy for metastatic melanoma","volume":"9","author":"Agarwala","year":"(2009)","journal-title":"Expert Rev. Anticancer Ther"},{"key":"key\n\t\t\t\t20170503060032_CIT0005","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"40","author":"Eggermont","year":"(2004)","journal-title":"Eur. J. Cancer"},{"key":"key\n\t\t\t\t20170503060032_CIT0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3747\/co.2007.97","article-title":"Single-agent interleukin-2 in the treatment of metastatic melanoma","volume":"14","author":"Petrella","year":"(2007)","journal-title":"Curr. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"(2010)","journal-title":"N. Engl. J. Med"},{"key":"key\n\t\t\t\t20170503060032_CIT0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"(2010)","journal-title":"N. Engl. J. Med"},{"key":"key\n\t\t\t\t20170503060032_CIT0009","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"(2009)","journal-title":"J. Clin. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0010","doi-asserted-by":"crossref","first-page":"vi8","DOI":"10.1093\/annonc\/mdp251","article-title":"Biomarkers in melanoma","volume":"20 (suppl. 6)","author":"Gogas","year":"(2009)","journal-title":"Ann. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0011","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ejca.2011.08.007","article-title":"Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma","volume":"48","author":"Egberts","year":"(2012)","journal-title":"Eur. J. Cancer"},{"key":"key\n\t\t\t\t20170503060032_CIT0012","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/286400a0","article-title":"S100 protein is present in cultured human malignant melanomas","volume":"286","author":"Gaynor","year":"(1980)","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170503060032_CIT0013","first-page":"419","article-title":"Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma","volume":"4","author":"Ghossein","year":"(1998)","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0014","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/ejso.2002.1366","article-title":"The role of molecular staging in malignant melanoma","volume":"29","author":"Prichard","year":"(2003)","journal-title":"Eur. J. Surg. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/CMR.0b013e328054c667","article-title":"Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients","volume":"17","author":"Quaglino","year":"(2007)","journal-title":"Melanoma Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0923-1811(99)00098-5","article-title":"gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients","volume":"23","author":"Tsukamoto","year":"(2000)","journal-title":"J. Dermatol. Sci"},{"key":"key\n\t\t\t\t20170503060032_CIT0017","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/onc.2010.58","article-title":"Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells","volume":"29","author":"Zanella","year":"(2010)","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170503060032_CIT0018","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/jnci\/djj103","article-title":"Gene expression profiling of primary cutaneous melanoma and clinical outcome","volume":"98","author":"Winnepenninckx","year":"(2006)","journal-title":"J. Natl. Cancer Inst"},{"key":"key\n\t\t\t\t20170503060032_CIT0019","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/modpathol.3800627","article-title":"Expression and possible role of hPTTG1\/securin in cutaneous malignant melanoma","volume":"19","author":"Winnepenninckx","year":"(2006)","journal-title":"Mod. Pathol"},{"key":"key\n\t\t\t\t20170503060032_CIT0020","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1158\/1078-0432.CCR-07-0408","article-title":"Prognostic significance of nuclear ING3 expression in human cutaneous melanoma","volume":"13","author":"Wang","year":"(2007)","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0021","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"(2008)","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0022","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1200\/JCO.2006.07.3833","article-title":"Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma","volume":"24","author":"Rangel","year":"(2006)","journal-title":"J. Clin. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0023","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cncr.23147","article-title":"Osteopontin as a molecular prognostic marker for melanoma","volume":"112","author":"Rangel","year":"(2008)","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170503060032_CIT0024","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/PAS.0b013e31816fd53c","article-title":"Novel role for RGS1 in melanoma progression","volume":"32","author":"Rangel","year":"(2008)","journal-title":"Am. J. Surg. Pathol"},{"key":"key\n\t\t\t\t20170503060032_CIT0025","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdm545","article-title":"HSP90 as a marker of progression in melanoma","volume":"19","author":"McCarthy","year":"(2008)","journal-title":"Ann. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0026","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/carcin\/bgn086","article-title":"Role of ING4 in human melanoma cell migration, invasion and patient survival","volume":"29","author":"Li","year":"(2008)","journal-title":"Carcinogenesis"},{"key":"key\n\t\t\t\t20170503060032_CIT0027","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1158\/1078-0432.CCR-05-0683","article-title":"Novel genes associated with malignant melanoma but not benign melanocytic lesions","volume":"11","author":"Talantov","year":"(2005)","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0028","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4161\/cbt.4.9.2165","article-title":"Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi\/melanoma in situ and advanced-stage melanomas","volume":"4","author":"Smith","year":"(2005)","journal-title":"Cancer Biol. Ther"},{"key":"key\n\t\t\t\t20170503060032_CIT0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1755-8794-1-13","article-title":"The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis","volume":"1","author":"Riker","year":"(2008)","journal-title":"BMC Med. Genomics"},{"key":"key\n\t\t\t\t20170503060032_CIT0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/sim.4780090710","article-title":"More powerful procedures for multiple significance testing","volume":"9","author":"Hochberg","year":"(1990)","journal-title":"Stat. Med"},{"key":"key\n\t\t\t\t20170503060032_CIT0031","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"(2001)","journal-title":"Methods"},{"key":"key\n\t\t\t\t20170503060032_CIT0032","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1600-0749.2007.00412.x","article-title":"DNA microarray analyses of melanoma gene expression: a decade in the mines","volume":"20","author":"Hoek","year":"(2007)","journal-title":"Pigment Cell Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0033","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/1471-2164-11-305","article-title":"Comparison and consolidation of microarray data sets of human tissue expression","volume":"11","author":"Russ","year":"(2010)","journal-title":"BMC Genomics"},{"key":"key\n\t\t\t\t20170503060032_CIT0034","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.2910300307","article-title":"Detection of S-100 protein as an aid to the identification of melanocytic tumors","volume":"30","author":"Cochran","year":"(1982)","journal-title":"Int. J. Cancer"},{"key":"key\n\t\t\t\t20170503060032_CIT0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/00313028509063777","article-title":"S-100 protein as a marker for melanocytic and other tumours","volume":"17","author":"Cochran","year":"(1985)","journal-title":"Pathology"},{"key":"key\n\t\t\t\t20170503060032_CIT0036","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00008390-199310000-00004","article-title":"S-100 protein remains a practical marker for melanocytic and other tumours","volume":"3","author":"Cochran","year":"(1993)","journal-title":"Melanoma Res"},{"key":"key\n\t\t\t\t20170503060032_CIT0037","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.cco.0000154039.07466.5d","article-title":"Biomarkers for melanoma","volume":"17","author":"Torabian","year":"(2005)","journal-title":"Curr. Opin. Oncol"},{"key":"key\n\t\t\t\t20170503060032_CIT0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18632\/oncotarget.1457","article-title":"Targeting nucleocytoplasmic transport in cancer therapy","volume":"5","author":"Hill","year":"(2014)","journal-title":"Oncotarget"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/36\/4\/469\/14134296\/bgv002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:52:32Z","timestamp":1598658752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article-lookup\/doi\/10.1093\/carcin\/bgv002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,13]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,1,13]]},"published-print":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgv002","relation":{},"ISSN":["1460-2180","0143-3334"],"issn-type":[{"value":"1460-2180","type":"electronic"},{"value":"0143-3334","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1,13]]}}}